ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Yong‐Su Zhen
Matched on OpenAlex author ID A5110364299. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 0, last author 9)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 11
- hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation. Co-author DOI 10.1016/j.bcp.2026.118222↗
- Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity and therapeutic efficacy against pancreat… Last author DOI 10.1016/j.ejps.2025.107188↗
- hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.3c01210↗
- The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer. Last author DOI 10.1016/j.bcp.2022.115057↗
- Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. Last author DOI 10.1016/j.jpha.2021.07.001↗
- DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Last author DOI 10.1080/15384047.2020.1776580↗
- An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibito… Last author DOI 10.3892/or.2020.7468↗
- The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation. Last author DOI 10.1186/s12935-019-0862-6↗
- A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.8b00234↗
- An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer. Last author DOI 10.7150/jca.22277↗
- A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Last author DOI 10.18632/oncotarget.11170↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qingfang Miao · 5 shared papers, 2016–2026 · strength 0.86
- Paper hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and… DOI 10.1016/j.bcp.2026.118222↗
- Paper Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. DOI 10.1016/j.jpha.2021.07.001↗
- Paper hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. DOI 10.1021/acs.jmedchem.3c01210↗
- Weijin Sheng · 6 shared papers, 2016–2025 · strength 0.84
- Paper Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity a… DOI 10.1016/j.ejps.2025.107188↗
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057↗
- Paper An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit … DOI 10.3892/or.2020.7468↗
- Ying Wang · 2 shared papers, 2025–2026 · strength 0.57
- Paper hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and… DOI 10.1016/j.bcp.2026.118222↗
- Paper Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity a… DOI 10.1016/j.ejps.2025.107188↗
- Liang Li · 2 shared papers, 2020–2022 · strength 0.31
- Paper Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer. DOI 10.1016/j.jpha.2021.07.001↗
- Paper An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit … DOI 10.3892/or.2020.7468↗
- D X Zhou · 1 shared paper, 2026 · strength 0.29
- Xiaofei Wang · 2 shared papers, 2018–2022 · strength 0.25
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057↗
- Paper A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Panc… DOI 10.1021/acs.molpharmaceut.8b00234↗
- Yangyang Wang · 1 shared paper, 2022 · strength 0.17
- Liping Sun · 1 shared paper, 2023 · strength 0.17
- Yibo Du · 1 shared paper, 2022 · strength 0.16
- Yanbo Zheng · 1 shared paper, 2020 · strength 0.15
- Yi Li · 1 shared paper, 2020 · strength 0.15
- Ruiqi L. Wang · 1 shared paper, 2019 · strength 0.11
- Genshen Zhong · 1 shared paper, 2018 · strength 0.09
- Shuzhen Chen · 1 shared paper, 2018 · strength 0.08
- Yue Du · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.